This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through September 7, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?
by Ahan Chakraborty
NVO's latest Hengrui deal adds a phase I-ready, once-weekly oral GLP-1/GIP candidate, building on deals for oral drug-delivery tech and small-molecule approaches.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Summit Shares Jump on $2B Strategic Investment From AstraZeneca
by Zacks Equity Research
SMMT shares jump as AstraZeneca commits $2 billion to accelerate ivonescimab development and expand clinical collaboration.
SMMTPositive Net Change AZNNegative Net Change PFENegative Net Change
biotechs medical pharmaceuticals
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo
by Zacks Equity Research
ABBV wins FDA approval for Juvmo, expanding its Parkinson's portfolio with a once-daily oral treatment and potential $5B-plus PD opportunity.
ABBVPositive Net Change ACIUNegative Net Change PGENPositive Net Change
biotechs medical pharmaceuticals
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
by Zacks Equity Research
MIRM's brelovitug meets the phase III AZURE-1 goal in chronic hepatitis delta virus, with strong virologic response and ALT normalization rates.
MIRMNegative Net Change REGNPositive Net Change PGENPositive Net Change
biotechs
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
by Zacks Equity Research
Keros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.
KROSPositive Net Change REGNPositive Net Change TAKNo Net Change PGENPositive Net Change
biotechs
Novo vs. Pfizer: Which Large Drugmaker Offers Better Growth Prospects?
by Ahan Chakraborty
NVO and PFE offer different growth paths, with diversified portfolios, pipelines and near-term challenges shaping their outlooks.
PFENegative Net Change NVONegative Net Change LLYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
by Zacks Equity Research
ACAD gains a potential patent extension for Daybue to 2041, while strong sales growth and EU approval expand trofinetide's reach.
ACADPositive Net Change ALDXNegative Net Change ACIUNegative Net Change PGENPositive Net Change
biotechnology biotechs medical pharmaceuticals
Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy
by Zacks Equity Research
MRK and Daiichi withdraw an FDA filing for ifinatamab deruxtecan after data falls short, while late-stage studies continue.
MRKPositive Net Change GSKNegative Net Change RHHBYNegative Net Change
biotechs medical pharmaceuticals
FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication
by Zacks Equity Research
FDA expands MRK's Welireg label for advanced kidney cancer, adding a third indication as sales climb and the drug gains wider use.
MRKPositive Net Change ACIUNegative Net Change PGENPositive Net Change
biotechs medical pharmaceuticals
Implied Volatility Surging for ANI Pharmaceuticals Stock Options
by Zacks Equity Research
Investors need to pay close attention to ANIP stock based on the movements in the options market lately.
ANIPNegative Net Change
biotechs medical pharmaceuticals